BREAKING
OpenEvidence Eyes $20B Valuation
0M
Potential raise
0B
Valuation
Valuation Doubling Each Round
Series B Jul253.5
Series C Oct256
Series D Jan2612
New round20
0%
US physicians
0M
Consultations
0M
Americans treated
Praised, But Not Without Limits
Strengths
Evidence-based, cited answers
Fast for broad questions
Ties to NEJM, JAMA, Cochrane
Concerns
14-46% accuracy on specialist cases
Metadata errors noted
Limited outcome studies
AI Moves Into Daily Clinical Care
AI NEWS BLITZ
OpenEvidence is weighing a new raise that could value it at roughly twenty billion dollars.